Eutilex.Co.Ltd (263050) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.083x

Based on the latest financial reports, Eutilex.Co.Ltd (263050) has a cash flow conversion efficiency ratio of -0.083x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.41 Billion ≈ $-1.63 Million USD) by net assets (₩28.91 Billion ≈ $19.59 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Eutilex.Co.Ltd market capitalisation for the company's overall valuation and market capitalisation.

Eutilex.Co.Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Eutilex.Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Eutilex.Co.Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Eutilex.Co.Ltd ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Eutilex.Co.Ltd to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Conduril - Engenharia S.A LS:CDU	N/A
Seach Medical Group Ltd TA:SEMG	-0.028x
Kim Teck Cheong Consolidated Bhd KLSE:0180	-0.102x
Shin Poong Pap KO:002870	0.008x
Cho Kwang Pain KO:004910	0.016x
WITTED MEGACORP OYJ EO 1 F:8OS	0.106x
Innature Bhd KLSE:5295	-0.063x
Lincoln Minerals Ltd AU:LML	-0.041x

Annual Cash Flow Conversion Efficiency for Eutilex.Co.Ltd (2016–2024)

The table below shows the annual cash flow conversion efficiency of Eutilex.Co.Ltd from 2016 to 2024. View Eutilex.Co.Ltd stock quote for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩39.94 Billion ≈ $27.07 Million	₩-21.40 Billion ≈ $-14.50 Million	-0.536x	-26.63%
2023-12-31	₩60.44 Billion ≈ $40.96 Million	₩-25.58 Billion ≈ $-17.33 Million	-0.423x	-24.17%
2022-12-31	₩87.75 Billion ≈ $59.47 Million	₩-29.90 Billion ≈ $-20.26 Million	-0.341x	+13.88%
2021-12-31	₩68.38 Billion ≈ $46.34 Million	₩-27.06 Billion ≈ $-18.34 Million	-0.396x	-30.05%
2020-12-31	₩58.51 Billion ≈ $39.65 Million	₩-17.80 Billion ≈ $-12.07 Million	-0.304x	-42.14%
2019-12-31	₩62.83 Billion ≈ $42.58 Million	₩-13.45 Billion ≈ $-9.11 Million	-0.214x	-62.31%
2018-12-31	₩77.49 Billion ≈ $52.52 Million	₩-10.22 Billion ≈ $-6.93 Million	-0.132x	-24.07%
2017-12-31	₩51.13 Billion ≈ $34.65 Million	₩-5.44 Billion ≈ $-3.68 Million	-0.106x	+25.20%
2016-12-31	₩25.87 Billion ≈ $17.53 Million	₩-3.68 Billion ≈ $-2.49 Million	-0.142x	--

About Eutilex.Co.Ltd

KQ:263050 Korea Biotechnology

Market Cap

$23.94 Million

₩35.32 Billion KRW

Market Cap Rank

#24620 Global

#1772 in Korea

Share Price

₩959.00

Change (1 day)

+29.95%

52-Week Range

₩683.00 - ₩1673.00

All Time High

₩41553.86